Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 369

1.

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37. doi: 10.1111/j.1365-2125.2008.03133.x.

2.

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:38-46. doi: 10.1111/j.1365-2125.2008.03134.x.

3.

Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.

Kaeser B, Zandt H, Bour F, Zwanziger E, Schmitt C, Zhang X.

Antimicrob Agents Chemother. 2009 Feb;53(2):609-14. doi: 10.1128/AAC.00769-08. Epub 2008 Nov 17.

4.

Maraviroc: in vitro assessment of drug-drug interaction potential.

Hyland R, Dickins M, Collins C, Jones H, Jones B.

Br J Clin Pharmacol. 2008 Oct;66(4):498-507. doi: 10.1111/j.1365-2125.2008.03198.x. Epub 2008 Apr 10.

5.

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.

Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:47-53. doi: 10.1111/j.1365-2125.2008.03135.x.

6.

CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.

Emmelkamp JM, Rockstroh JK.

Eur J Med Res. 2007 Oct 15;12(9):409-17. Review.

PMID:
17933722
7.

Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.

Vourvahis M, Fang J, Checchio T, Milton A, Weatherley B, McFadyen L, Heera J.

HIV Clin Trials. 2013 May-Jun;14(3):99-109. doi: 10.1310/hct1403-99.

PMID:
23835512
8.

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.

Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:5-18. doi: 10.1111/j.1365-2125.2008.03130.x.

9.
10.

The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.

Adkison KK, Shachoy-Clark A, Fang L, Lou Y, Otto VR, Berrey MM, Piscitelli SC.

Br J Clin Pharmacol. 2006 Sep;62(3):336-44.

11.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
12.

A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.

Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ.

Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:54-9. doi: 10.1111/j.1365-2125.2008.03136.x.

13.

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.

Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, Butterton JR.

Clin Infect Dis. 2013 Mar;56(5):718-26. doi: 10.1093/cid/cis968. Epub 2012 Nov 15.

PMID:
23155151
14.

Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.

Jamois C, Smith P, Morrison R, Riek M, Patel A, Schmitt C, Morcos PN, Zhang X.

Addict Biol. 2009 Jul;14(3):321-7. doi: 10.1111/j.1369-1600.2009.00158.x.

PMID:
19523046
15.

Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).

Walmsley SL, Katlama C, Lazzarin A, Arestéh K, Pierone G, Blick G, Johnson M, Meier U, MacGregor TR, Leith JG.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):429-40. doi: 10.1097/QAI.0b013e318160a529.

PMID:
18176328
16.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
17.

Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.

Kakuda TN, Abel S, Davis J, Hamlin J, Schöller-Gyüre M, Mack R, Ndongo N, Petit W, Ridgway C, Sekar V, Tweedy S, Hoetelmans RM.

Antimicrob Agents Chemother. 2011 May;55(5):2290-6. doi: 10.1128/AAC.01046-10. Epub 2011 Mar 7.

18.
19.

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.

AIDS. 2006 May 12;20(8):1131-9.

PMID:
16691064
20.

Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.

Huang F, Allen L, Huang DB, Moy F, Vinisko R, Nguyen T, Rowland L, MacGregor TR, Castles MA, Robinson P.

J Clin Pharm Ther. 2012 Feb;37(1):81-8. doi: 10.1111/j.1365-2710.2010.01235.x. Epub 2010 Dec 5.

PMID:
21128991

Supplemental Content

Support Center